bluebird bio (NASDAQ:BLUE) Stock Rating Upgraded by StockNews.com

bluebird bio (NASDAQ:BLUE) was upgraded by StockNews.com to a “sell” rating in a research note issued to investors on Thursday.

A number of other brokerages also recently issued reports on BLUE. Bank of America lowered their price target on bluebird bio from $12.00 to $5.00 and set a “buy” rating for the company in a report on Thursday, December 21st. Wedbush lowered their target price on shares of bluebird bio from $1.72 to $1.68 and set a “neutral” rating for the company in a report on Tuesday, March 19th. HSBC cut their price target on shares of bluebird bio from $2.31 to $1.02 and set a “reduce” rating on the stock in a research note on Tuesday, March 5th. Royal Bank of Canada reissued a “sector perform” rating and issued a $6.00 price target on shares of bluebird bio in a research report on Wednesday. Finally, Wells Fargo & Company dropped their price objective on bluebird bio from $4.00 to $3.00 and set an “equal weight” rating on the stock in a report on Wednesday. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $5.87.

bluebird bio Stock Performance

Shares of NASDAQ:BLUE traded down $0.08 on Thursday, hitting $1.28. 7,253,083 shares of the company’s stock were exchanged, compared to its average volume of 9,900,090. bluebird bio has a 1-year low of $0.88 and a 1-year high of $5.53. The company has a market capitalization of $139.96 million, a PE ratio of -1.73 and a beta of 0.75. The firm’s 50-day moving average is $1.24 and its 200 day moving average is $2.27.

Hedge Funds Weigh In On bluebird bio

Institutional investors have recently added to or reduced their stakes in the stock. US Bancorp DE increased its holdings in shares of bluebird bio by 885.7% in the second quarter. US Bancorp DE now owns 7,511 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 6,749 shares during the period. GSA Capital Partners LLP acquired a new position in bluebird bio in the 4th quarter valued at $29,000. Stifel Financial Corp acquired a new position in bluebird bio in the 3rd quarter valued at $32,000. Aigen Investment Management LP purchased a new position in bluebird bio during the 3rd quarter worth $34,000. Finally, Sequoia Financial Advisors LLC acquired a new stake in shares of bluebird bio in the 4th quarter worth $37,000. Institutional investors and hedge funds own 87.43% of the company’s stock.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.